Edition:
United Kingdom

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

84.06USD
16 Aug 2019
Change (% chg)

$2.33 (+2.85%)
Prev Close
$81.73
Open
$82.79
Day's High
$84.93
Day's Low
$82.11
Volume
178,079
Avg. Vol
157,540
52-wk High
$102.37
52-wk Low
$45.15

Latest Key Developments (Source: Significant Developments)

Blueprint Medicines Reports Second Quarter 2019 Financial Results
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $2.04.Q2 EARNINGS PER SHARE ESTIMATE $-1.91 -- REFINITIV IBES DATA.BLUEPRINT MEDICINES - AS OF JUNE 30, 2019, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $667.3 MILLION, AS COMPARED TO $494.0 MILLION AS OF DECEMBER 31, 2018.BLUEPRINT MEDICINES - COLLABORATION REVENUES WERE $5.1 MILLION FOR Q2 OF 2019, AS COMPARED TO $41.4 MILLION FOR Q2 OF 2018.BLUEPRINT MEDICINES - SEES EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS TO BE SUFFICIENT TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS TO MIDDLE OF 2021.  Full Article

Blueprint Medicines - On June 28, Entered Into 5Th Amendment To Collaboration & License Agreement With F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES - ON JUNE 28, ENTERED INTO 5TH AMENDMENT TO COLLABORATION & LICENSE AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD, HOFFMANN-LA ROCHE INC.BLUEPRINT MEDICINES - CO, ROCHE AGREED TO MODIFY CERTAIN TIME PERIODS RELATED TO SCREENING ACTIVITIES AND CRITERIA RELATED TO LEFTOVER TARGETS.  Full Article

Blueprint Medicines Submits New Drug Application For Avapritinib
Friday, 14 Jun 2019 

June 14 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR AVAPRITINIB FOR THE TREATMENT OF PDGFRA EXON 18 MUTANT GIST AND FOURTH-LINE GIST.BLUEPRINT MEDICINES CORP - HAS REQUESTED PRIORITY REVIEW FOR APPLICATION.  Full Article

Blueprint Medicines Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $1.98.Q1 EARNINGS PER SHARE ESTIMATE $-1.86 -- REFINITIV IBES DATA.BLU-667 GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF RET FUSION-POSITIVE NSCLC.AVAPRITINIB NDA FOR PDGFRA EXON 18 MUTANT GIST AND FOURTH-LINE GIST ON TRACK FOR SUBMISSION TO FDA IN Q2.QTRLY NET LOSS PER SHARE OF $1.98.BLUEPRINT MEDICINES - AS OF MARCH 31, 2019, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $415.9 MILLION, AS COMPARED TO $494.0 MILLION AS OF DECEMBER 31, 2018.  Full Article

Blueprint Medicines Prices Underwritten Public Offering Of 4.05 Mln Shares
Friday, 29 Mar 2019 

March 28 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK.PRICES UNDERWRITTEN PUBLIC OFFERING OF 4.05 MILLION SHARES OF ITS COMMON STOCK AT $74.00 PER SHARE.  Full Article

Blueprint Medicines Corp, On Jan 30, Board Promoted Michael Landsittel To CFO
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Blueprint Medicines Corp ::ON JANUARY 30, 2019, BOARD PROMOTED MICHAEL LANDSITTEL TO CFO.  Full Article

Blueprint Medicines Says Top-Line Avapritinib Data Support Planned NDA Submission In H1 2019
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES "2020 BLUEPRINT" GLOBAL BUSINESS STRATEGY AND OUTLINES KEY CORPORATE GOALS.BLUEPRINT MEDICINES CORP - TOP-LINE AVAPRITINIB DATA SUPPORT PLANNED NDA FOR PDGFRA EXON 18 MUTANT GIST AND FOURTH-LINE GIST IN FIRST HALF 2019.BLUEPRINT MEDICINES CORP - IND APPLICATION CLEARED BY FDA FOR BLU-782.BLUEPRINT MEDICINES - FOR BLU-782, PHASE 1 HEALTHY VOLUNTEER TRIAL ON TRACK TO INITIATE IN Q1 2019.BLUEPRINT MEDICINES CORP - IND APPLICATION APPROVED IN CHINA FOR ONGOING GLOBAL PHASE 1 TRIAL OF BLU-554 IN ADVANCED HEPATOCELLULAR CARCINOMA.  Full Article

Blueprint Medicines Announces Updated Navigator Trial Results In Patients With Advanced Gastrointestinal Stromal Tumors
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES UPDATED NAVIGATOR TRIAL RESULTS IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS SUPPORTING DEVELOPMENT OF AVAPRITINIB ACROSS ALL LINES OF THERAPY.BLUEPRINT MEDICINES CORP - AVAPRITINIB WAS WELL-TOLERATED WITH MOST ADVERSE EVENTS (AES) REPORTED BY INVESTIGATORS AS GRADE 1 OR 2.BLUEPRINT MEDICINES - UPDATED DATA FROM ONGOING PHASE 1 NAVIGATOR TRIAL SUPPORT CO'S PLANS TO SUBMIT NDA IN H1 2019 TO U.S. FDA.BLUEPRINT MEDICINES - AVAPRITINIB DEMONSTRATED ORR OF 26 PERCENT IN REGORAFENIB-NAÏVE THIRD- AND FOURTH-LINE GIST & ORR OF 25 PERCENT IN SECOND-LINE GIST.  Full Article

Blueprint Medicines Reports Q3 2018 Financial Results
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.66.Q3 EARNINGS PER SHARE VIEW $-1.51 -- THOMSON REUTERS I/B/E/S.RECEIVED FDA FEEDBACK SUPPORTING EXPEDITED DEVELOPMENT OF BLU-667.PLANS TO SUBMIT AN NDA FOR BLU-667 IN FIRST HALF OF 2020 BASED ON ADDITIONAL DATA FROM ONGOING PHASE 1 ARROW TRIAL.  Full Article

Blueprint Medicines And CStone Pharma To Collaborate To Develop Avapritinib, Blu-554 And Blu-667 In Greater China
Monday, 4 Jun 2018 

June 4 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES AND CSTONE PHARMACEUTICALS ANNOUNCE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE AVAPRITINIB, BLU-554 AND BLU-667 IN GREATER CHINA.BLUEPRINT MEDICINES CORP - BLUEPRINT MEDICINES TO RECEIVE $40 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO $346 MILLION IN POTENTIAL MILESTONES.BLUEPRINT MEDICINES - CSTONE PHARMACEUTICALS WILL BE OBLIGATED TO PAY CO TIERED PERCENTAGE ROYALTIES ON A LICENSED PRODUCT-BY-LICENSED PRODUCT BASIS.BLUEPRINT MEDICINES - CSTONE PHARMACEUTICALS RESPONSIBLE FOR CONDUCTING DEVELOPMENT, COMMERCIAL ACTIVITIES IN TERRITORY RELATED TO LICENSED PRODUCTS.BLUEPRINT MEDICINES CORP - CSTONE PHARMACEUTICALS WILL BE RESPONSIBLE FOR COSTS RELATED TO DEVELOPMENT OF LICENSED PRODUCTS IN TERRITORY.BLUEPRINT MEDICINES- SPECIFIED COSTS RELATED TO DEVELOPMENT OF BLU-554 AS COMBINATION THERAPY IN TERRITORY TO BE SHARED BY CO, CSTONE PHARMACEUTICALS.  Full Article

UPDATE 3-Deciphera shares skyrocket as cancer drug improves progression-free survival

Aug 13 Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study.